These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 18937615)

  • 41. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence and management of gynecomastia in men treated for prostate cancer.
    Dobs A; Darkes MJ
    J Urol; 2005 Nov; 174(5):1737-42. PubMed ID: 16217274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnosis and Management of Gynecomastia for Urologists.
    Baumgarten L; Dabaja AA
    Curr Urol Rep; 2018 May; 19(7):46. PubMed ID: 29774423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of Androgen Deprivation Therapy-Associated Hot Flashes in Men With Prostate Cancer.
    Qan'ir Y; DeDeaux D; Godley PA; Mayer DK; Song L
    Oncol Nurs Forum; 2019 Jul; 46(4):E107-E118. PubMed ID: 31225840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
    Walker LM; Tran S; Robinson JW
    Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR
    Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review.
    Gardner JR; Livingston PM; Fraser SF
    J Clin Oncol; 2014 Feb; 32(4):335-46. PubMed ID: 24344218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Indications and Complications of Androgen Deprivation Therapy.
    Fankhauser CD; Wettstein MS; Reinhardt M; Gessendorfer A; Mostafid H; Hermanns T
    Semin Oncol Nurs; 2020 Aug; 36(4):151042. PubMed ID: 32773255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer.
    Famili P; Cauley JA; Greenspan SL
    J Urol; 2007 Mar; 177(3):921-4. PubMed ID: 17296376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Androgen deprivation therapy for prostate cancer: adverse effects and their management].
    Arai G; Okada H
    Nihon Rinsho; 2016 May; 74 Suppl 3():605-9. PubMed ID: 27344802
    [No Abstract]   [Full Text] [Related]  

  • 54. Complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM; McLaughlin MD; Thrasher JB
    Curr Opin Urol; 2004 May; 14(3):177-83. PubMed ID: 15069309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of side effects of androgen deprivation therapy.
    Grossmann M; Zajac JD
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):655-71, x. PubMed ID: 21889727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The management of hot flushes for men treated with androgen deprivation therapy for prostate cancer: a survey of UK practice.
    Kinnaird W; Mehta A; Guo C; Payne H; Jenkins V; Catt S
    Acupunct Med; 2021 Aug; 39(4):394-395. PubMed ID: 33023298
    [No Abstract]   [Full Text] [Related]  

  • 57. [Combined hormonotherapy with external beam radiotherapy in locally advanced prostate cancer: do side effects overlap the advantages?].
    Drouin SJ; Rouprêt M; Bossi A; Bolla M
    Prog Urol; 2010 Jun; 20 Suppl 3():S186-91. PubMed ID: 20620963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
    J Urol; 2013 Jan; 189(1 Suppl):S45-50. PubMed ID: 23234631
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
    Mohamad NV; Soelaiman IN; Chin KY
    Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The evolving role of androgen deprivation therapy in the management of prostate cancer.
    Cooperberg MR; Small EJ; D'Amico A; Carroll PR
    Minerva Urol Nefrol; 2003 Dec; 55(4):219-38. PubMed ID: 14765015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.